Long-term safety of satralizumab in NMOSD

被引：0
|
作者：
Lempriere, Sarah
机构：
来源：
NATURE REVIEWS NEUROLOGY | 2022年 / 18卷 / 09期
关键词：
D O I：
10.1038/s41582-022-00709-7
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：510 / 510
页数：1
相关论文
共 50 条
  • [1] Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar
    Yamamura, Takashi
    Weinshenker, Brian
    Yeaman, Michael R.
    De Seze, Jerome
    Patti, Francesco
    Lobo, Patricia
    Von Buedingen, H-Christian
    Kou, Xiujing
    Weber, Kristina
    Greenberg, Benjamin
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 66
  • [2] Long-term Efficacy and Safety of Satralizumab in Adults with AQP4-IgG-seropositive Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the Phase 3 SAkura studies
    Bennett, J. L.
    Fox, E.
    Greenberg, B.
    Weinshenker, B. G.
    Traboulsee, A.
    Yeaman, M. R.
    Blondeau, K.
    Weber, K.
    Gholizadeh, S.
    Vodopivec, I.
    Levy, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 146 - 146
  • [3] Long-term efficacy and safety of satralizumab in adults with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD): results from the Phase 3 SAkura studies
    Moghaddam, Shervin Gholizadeh
    Bennett, Jeffrey L.
    Fox, Edward
    Greenberg, Benjamin
    Weinshenker, Brian G.
    Traboulsee, Anthony
    Yeaman, Michael R.
    Blondeau, Kathleen
    Weber, Kristina
    Vodopivec, Ivana
    Levy, Michael
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [4] Long-term Safety of Satralizumab in Adults with Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from SAkuraMoon
    Weinshenker, Brian
    Yeaman, Michael R.
    de Seze, Jerome
    Patti, Francesco
    Vodopivec, Ivana
    Blondeau, Kathleen
    Klingelschmitt, Gaelle
    Marcillat, Carole
    Greenberg, Benjamin M.
    Gholizadeh, Shervin
    NEUROLOGY, 2023, 100 (17)
  • [5] EFFICACY OF SATRALIZUMAB THERAPY IN THE TREATMENT OF NMOSD
    Krzyzanowska, Malgorzata
    Kozon, Katarzyna
    Olszewski, Jakub
    Patyra, Andrzej
    PROSPECTS IN PHARMACEUTICAL SCIENCES, 2023, (03): : 64 - 68
  • [6] Long-term efficacy of satralizumab in patients with AQP4-IgG+ NMOSD: Updated analysis from the open-label SAkuraMoon study
    Palace, Jacqueline
    Traboulsee, Anthony
    Saiz, Albert
    De Seze, Jerome
    Kleiter, Ingo
    Bennett, Jeffrey L.
    Stokmaier, Daniela
    Klingelschmitt, Gaelle
    Te-Ying, Audrey Yeo
    Vodopivec, Ivana
    Yamamura, Takashi
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1052 - 1053
  • [7] Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD
    Wingerchuk, Dean M.
    Fujihara, Kazuo
    Palace, Jacqueline
    Berthele, Achim
    Levy, Michael
    Kim, Ho Jin
    Nakashima, Ichiro
    Oreja-Guevara, Celia
    Wang, Kai-Chen
    Miller, Larisa
    Shang, Shulian
    Sabatella, Guido
    Yountz, Marcus
    Pittock, Sean J.
    ANNALS OF NEUROLOGY, 2021, 89 (06) : 1088 - 1098
  • [8] Infection in NMOSD: An analysis of the patterns of infection in SAkuraMoon (an open-label study to evaluate the long-term safety and efficacy of satralizumab) with post-marketing data and US-based health claims data
    Greenberg, Benjamin M.
    Fujihara, Kazuo
    Weinshenker, Brian
    Patti, Francesco
    Kleiter, Ingo
    Bennett, Jeffrey L.
    Palace, Jacqueline
    Triyatni, Miriam
    Blondeau, Kathleen
    Burdeska, Alexander
    Ngwa, Innocent
    Klingelschmitt, Gaelle
    Yamamura, Takashi
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 349 - 350
  • [9] Long-term Efficacy and Safety of Satralizumab in Adults with AQP4-IgG-seropositive Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the Roll-over, Open-label Study SAkuraMoon
    Bennett, J. L.
    Greenberg, B.
    Weinshenker, B. G.
    Traboulsee, A.
    Yeaman, M. R.
    Javed, A.
    Blondeau, K.
    Klingelschmitt, G.
    Marcillat, C.
    Gholizadeh, S.
    Vodopivec, I.
    Levy, M.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 168 - 169
  • [10] MODELLING THE LONG-TERM EFFECTIVENESS OF INEBILIZUMAB IN THE CURRENT TREATMENT LANDSCAPE OF NMOSD
    Pedersen, M.
    Vilela, F. Sorio
    Patterson, K.
    Rampal, N.
    Cimbora, D.
    Paul, F.
    VALUE IN HEALTH, 2023, 26 (06) : S43 - S44
12345